| Year |
Citation |
Score |
| 2023 |
Redmond WL, Kasiewicz MJ, Akporiaye ET. Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA. Frontiers in Immunology. 14: 1057702. PMID 36911733 DOI: 10.3389/fimmu.2023.1057702 |
0.414 |
|
| 2019 |
Guerrouahen BS, Maccalli C, Cugno C, Rutella S, Akporiaye ET. Reverting Immune Suppression to Enhance Cancer Immunotherapy. Frontiers in Oncology. 9: 1554. PMID 32039024 DOI: 10.3389/Fonc.2019.01554 |
0.436 |
|
| 2019 |
Polanczyk MJ, Walker E, Haley D, Guerrouahen BS, Akporiaye ET. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4CD25Foxp3 and CD4CD25Foxp3 T cells. Journal of Translational Medicine. 17: 219. PMID 31288845 DOI: 10.1186/S12967-019-1967-3 |
0.435 |
|
| 2016 |
Crittenden MR, Baird J, Friedman D, Savage T, Uhde L, Alice A, Cottam B, Young K, Newell P, Nguyen C, Bambina S, Kramer G, Akporiaye E, Malecka A, Jackson A, et al. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget. PMID 27602953 DOI: 10.18632/Oncotarget.11823 |
0.449 |
|
| 2016 |
Althammer S, Steele K, Rebelatto M, Tan TH, Wiestler T, Schmidt G, Higgs B, Li X, Shi L, Jin X, Antal J, Gupta A, Ranade K, Binning G, Bellmunt J, ... ... Akporiaye E, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0191-4 |
0.304 |
|
| 2015 |
Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade. Cancer Immunology Research. 3: 526-35. PMID 25627655 DOI: 10.1158/2326-6066.CIR-14-0187 |
0.422 |
|
| 2014 |
Young KH, Newell P, Cottam B, Friedman D, Savage T, Baird JR, Akporiaye E, Gough MJ, Crittenden M. TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. Cancer Immunology Research. 2: 1011-22. PMID 25047233 DOI: 10.1158/2326-6066.Cir-13-0207 |
0.443 |
|
| 2013 |
Hahn T, Akporiaye ET. α-TEA as a stimulator of tumor autophagy and enhancer of antigen cross-presentation. Autophagy. 9: 429-31. PMID 23235369 DOI: 10.4161/Auto.22969 |
0.47 |
|
| 2013 |
Hahn T, Polanczyk MJ, Borodovsky A, Ramanathapuram LV, Akporiaye ET, Ralph SJ. Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. Current Pharmaceutical Biotechnology. 14: 357-76. PMID 22201597 DOI: 10.2174/1389201011314030010 |
0.759 |
|
| 2013 |
Akporiaye ET, Tucker C, Triplett T, Garrison K, Sun L, Ling L, Weinberg A. STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P68 |
0.429 |
|
| 2013 |
Young KH, Cottam B, Savage T, Baird J, Friedman D, Akporiaye E, Gough MJ, Crittenden M. Improved efficacy of radiation in combination with TGFβ inhibition in a colorectal cancer mouse model Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P120 |
0.506 |
|
| 2012 |
Li Y, Hahn T, Garrison K, Cui ZH, Thorburn A, Thorburn J, Hu HM, Akporiaye ET. The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Research. 72: 3535-45. PMID 22745370 DOI: 10.1158/0008-5472.Can-11-3103 |
0.483 |
|
| 2012 |
Hahn T, Akporiaye ET. Repeat dose study of the novel proapoptotic chemotherapeutic agent alpha-tocopheryloxy acetic acid in mice. Anti-Cancer Drugs. 23: 455-64. PMID 22185820 DOI: 10.1097/Cad.0B013E32834F6271 |
0.318 |
|
| 2012 |
Dong LF, Grant G, Massa H, Zobalova R, Akporiaye E, Neuzil J. α-Tocopheryloxyacetic acid is superior to α-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability. International Journal of Cancer. 131: 1052-8. PMID 22038845 DOI: 10.1002/Ijc.26489 |
0.33 |
|
| 2012 |
Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD, Akporiaye ET. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunology, Immunotherapy : Cii. 61: 511-21. PMID 21971588 DOI: 10.1007/S00262-011-1119-Y |
0.537 |
|
| 2011 |
Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. Bmc Cancer. 11: 471. PMID 22044845 DOI: 10.1186/1471-2407-11-471 |
0.442 |
|
| 2011 |
Zobalova R, Prokopova K, Stantic M, Stapelberg M, Dong LF, Ralph SJ, Akporiaye E, Neuzil J. The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection? Antioxidants & Redox Signaling. 15: 2989-3002. PMID 21504364 DOI: 10.1089/Ars.2010.3785 |
0.426 |
|
| 2011 |
Hahn T, Jagadish B, Mash EA, Garrison K, Akporiaye ET. α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. Breast Cancer Research : Bcr. 13: R4. PMID 21232138 DOI: 10.1186/Bcr2808 |
0.413 |
|
| 2009 |
Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, ... Akporiaye E, et al. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Current Molecular Medicine. 9: 673-82. PMID 19689294 DOI: 10.2174/156652409788970670 |
0.454 |
|
| 2009 |
Rausch MP, Hahn T, Ramanathapuram L, Bradley-Dunlop D, Mahadevan D, Mercado-Pimentel ME, Runyan RB, Besselsen DG, Zhang X, Cheung HK, Lee WC, Ling LE, Akporiaye ET. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer. Anticancer Research. 29: 2099-109. PMID 19528470 |
0.794 |
|
| 2009 |
Hahn T, Fried K, Hurley LH, Akporiaye ET. Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Molecular Cancer Therapeutics. 8: 1570-8. PMID 19509249 DOI: 10.1158/1535-7163.Mct-08-1079 |
0.481 |
|
| 2007 |
Dong LF, Swettenham E, Eliasson J, Wang XF, Gold M, Medunic Y, Stantic M, Low P, Prochazka L, Witting PK, Turanek J, Akporiaye ET, Ralph SJ, Neuzil J. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Research. 67: 11906-13. PMID 18089821 DOI: 10.1158/0008-5472.Can-07-3034 |
0.334 |
|
| 2007 |
Akporiaye ET, Bradley-Dunlop D, Gendler SJ, Mukherjee P, Madsen CS, Hahn T, Besselsen DG, Dial SM, Cui H, Trevor K. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine. 25: 6965-74. PMID 17707958 DOI: 10.1016/J.Vaccine.2007.06.063 |
0.356 |
|
| 2007 |
Neuzil J, Dong LF, Ramanathapuram L, Hahn T, Chladova M, Wang XF, Zobalova R, Prochazka L, Gold M, Freeman R, Turanek J, Akporiaye ET, Dyason JC, Ralph SJ. Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria. Molecular Aspects of Medicine. 28: 607-45. PMID 17499351 DOI: 10.1016/J.Mam.2007.02.003 |
0.73 |
|
| 2007 |
Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine. 25: 1607-18. PMID 17166639 DOI: 10.1016/J.Vaccine.2006.11.007 |
0.531 |
|
| 2006 |
Hahn T, Szabo L, Gold M, Ramanathapuram L, Hurley LH, Akporiaye ET. Dietary administration of the proapoptotic vitamin E analogue alpha-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Research. 66: 9374-8. PMID 17018590 DOI: 10.1158/0008-5472.Can-06-2403 |
0.763 |
|
| 2006 |
Hahn T, Alvarez I, Kobie JJ, Ramanathapuram L, Dial S, Fulton A, Besselsen D, Walker E, Akporiaye ET. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. International Journal of Cancer. Journal International Du Cancer. 118: 2220-31. PMID 16331615 DOI: 10.1002/Ijc.21616 |
0.812 |
|
| 2006 |
Ramanathapuram LV, Hahn T, Graner MW, Katsanis E, Akporiaye ET. Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunology, Immunotherapy : Cii. 55: 166-77. PMID 16041582 DOI: 10.1007/S00262-005-0016-7 |
0.795 |
|
| 2005 |
Ramanathapuram LV, Hahn T, Dial SM, Akporiaye ET. Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination. Nutrition and Cancer. 53: 177-93. PMID 16573379 DOI: 10.1207/S15327914Nc5302_7 |
0.815 |
|
| 2005 |
Rausch MP, Mahadevan D, Akporiaye ET. Enhancement of Dendritic Cell-Based Immunotherapy Using A Small Molecule TGF-?? Receptor Type I (TGF-??RI) Kinase Inhibitor Journal of Immunotherapy. 28: 651. DOI: 10.1097/01.Cji.0000191075.57371.3B |
0.342 |
|
| 2004 |
Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romanoski A, Thompson S, Akporiaye E, Katsanis E. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Research. 64: 8085-92. PMID 15520220 DOI: 10.1158/0008-5472.Can-04-1871 |
0.515 |
|
| 2004 |
Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer. 101: 2557-66. PMID 15517589 DOI: 10.1002/Cncr.20653 |
0.323 |
|
| 2004 |
Trevor KT, Cover C, Ruiz YW, Akporiaye ET, Hersh EM, Landais D, Taylor RR, King AD, Walters RE. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunology, Immunotherapy : Cii. 53: 705-14. PMID 15048588 DOI: 10.1007/S00262-004-0512-1 |
0.511 |
|
| 2004 |
Ramanathapuram LV, Kobie JJ, Bearss D, Payne CM, Trevor KT, Akporiaye ET. alpha-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. Cancer Immunology, Immunotherapy : Cii. 53: 580-8. PMID 14991239 DOI: 10.1007/S00262-004-0499-7 |
0.798 |
|
| 2004 |
Hahn T, Alvarez I, Ramanathapuram L, Dial S, Akporiaye E. Dietary Celecoxib Enhances the Efficacy of Tumor Lysate-Pulsed Dendritic Cell Vaccines in Treating Murine Breast Cancer Journal of Immunotherapy. 27: S22-S23. DOI: 10.1097/00002371-200411000-00083 |
0.783 |
|
| 2003 |
Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Research. 63: 1860-4. PMID 12702574 |
0.771 |
|
| 2003 |
Kobie JJ, Akporiaye ET. Immunosuppressive role of transforming growth factor beta in breast cancer Clinical and Applied Immunology Reviews. 3: 277-287. DOI: 10.1016/S1529-1049(03)00011-4 |
0.729 |
|
| 2002 |
Robey IF, Schluter SF, Akporiaye E, Yocum DE, Marchalonis JJ. Human monoclonal natural autoantibodies against the T-cell receptor inhibit interleukin-2 production in murine T cells. Immunology. 105: 419-29. PMID 11985662 DOI: 10.1046/J.1365-2567.2002.01389.X |
0.34 |
|
| 2001 |
Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, McEarchern JA, Akporiaye ET. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunology, Immunotherapy : Cii. 50: 229-40. PMID 11499806 DOI: 10.1007/S002620100197 |
0.812 |
|
| 2001 |
McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. International Journal of Cancer. 91: 76-82. PMID 11149423 DOI: 10.1002/1097-0215(20010101)91:1<76::Aid-Ijc1012>3.0.Co;2-8 |
0.773 |
|
| 2000 |
Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines Cancer Immunology Immunotherapy. 49: 476-484. PMID 11092614 DOI: 10.1007/S002620000138 |
0.424 |
|
| 2000 |
Kurt RA, Park JA, Schluter SF, Marchalonis JJ, Akporiaye ET. TCR V(β) usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture International Immunology. 12: 639-646. PMID 10784610 DOI: 10.1093/Intimm/12.5.639 |
0.471 |
|
| 2000 |
Tsang TC, Brailey JL, Vasanwala FH, Wu RS, Liu F, Clark PR, Meade-Tollin L, Luznick L, Stopeck AT, Akporiaye ET, Harris DT. Construction of new amplifier expression vectors for high levels of IL-2 gene expression. International Journal of Molecular Medicine. 5: 295-300. PMID 10677573 |
0.705 |
|
| 2000 |
Tsang TC, Brailey JL, Vasanwala FH, Wu RS, Liu F, Clark PR, Meade-Tollin L, Luznick L, Stopeck AT, Akporiaye ET, Harris DT. Construction of new amplifier expression vectors for high levels of IL-2 gene expression. International Journal of Molecular Medicine. 5: 295-300. DOI: 10.3892/Ijmm.5.3.295 |
0.717 |
|
| 1999 |
McEarchern JA, Besselsen DG, Akporiaye ET. Interferon gamma and antisense transforming growth factor beta transgenes synergize to enhance the immunogenicity of a murine mammary carcinoma. Cancer Immunology, Immunotherapy : Cii. 48: 63-70. PMID 10414459 DOI: 10.1007/S002620050549 |
0.586 |
|
| 1996 |
Panelli MC, Wang E, Shen S, Schluter SF, Bernstein RM, Hersh EM, Stopeck A, Gangavalli R, Barber J, Jolly D, Akporiaye ET. Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Cancer Immunology, Immunotherapy : Cii. 42: 99-107. PMID 8620527 DOI: 10.1007/S002620050258 |
0.49 |
|
| 1995 |
Park JA, Brown RA, Kurt RA, Akporiaye ET. Studies of in vivo recruitment and activation of cytotoxic lymphocytes using a gelatin-sponge model of concomitant tumor immunity International Journal of Cancer. 62: 421-427. PMID 7543457 DOI: 10.1002/Ijc.2910620411 |
0.515 |
|
| 1994 |
Akporiaye ET, Petersen A, Pierce P, Valenzuela J, Canfield L, Bender J. Effect of beta-carotene on cytotoxic activity and receptor expression of tumor-specific lymphocytes. Annals of the New York Academy of Sciences. 691: 264-6. PMID 8129307 DOI: 10.1111/J.1749-6632.1993.Tb26190.X |
0.48 |
|
| 1991 |
Akporiaye ET, Barbieri CA, Stewart CC, Bender JG. Gelatin sponge model of effector recruitment: Tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2 Journal of Leukocyte Biology. 49: 189-196. PMID 1991999 DOI: 10.1002/jlb.49.2.189 |
0.324 |
|
| 1989 |
Akporiaye ET, Kudalore MK. Implantation of a gelatin-sponge as a model for effector recruitment. Tumor growth inhibition by T-lymphocytes recovered from a site of tumor rejection. Cancer Immunology, Immunotherapy : Cii. 29: 199-204. PMID 2786457 DOI: 10.1007/Bf00199996 |
0.515 |
|
| 1987 |
Akporiaye ET, Saunders GC, Kraemer PM. A gelatin sponge model for studying tumor growth: quantitation of tumor cells and leukocytes in the CHO tumor. Experientia. 43: 589-93. PMID 3595790 DOI: 10.1007/BF02126340 |
0.391 |
|
| Show low-probability matches. |